Aug 7, 2025 04:31PM Annexon selected for EMA pilot program for dry AMD treatment

May 19, 2025 04:07PM Annexon (ANNX) Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS)

May 13, 2025 07:55AM Cantor Fitzgerald Reiterates Overweight Rating on Annexon Biosciences (ANNX)

May 13, 2025 06:19AM Annexon, Inc. (ANNX) Misses Q1 EPS by 7c

Mar 5, 2025 06:45AM Annexon Biosciences (ANNX) PT Lowered to $20 at H.C. Wainwright

Mar 3, 2025 04:26PM Annexon, Inc. (ANNX) Misses Q4 EPS by 6c

Jan 13, 2025 08:13AM Annexon (ANNX) Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year

Dec 17, 2024 06:53AM H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

Dec 17, 2024 04:43AM Annexon Biosciences (ANNX) PT Raised to $12 at BofA Securities

Dec 16, 2024 07:31AM Annexon (ANNX) Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin or Plasma Exchange

Oct 23, 2024 07:49AM TD Cowen Reiterates Buy Rating on Annexon Biosciences (ANNX)

Oct 15, 2024 08:02AM Annexon (ANNX) to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 1, 2024 06:45AM Wells Fargo Adds Annexon Biosciences (ANNX) to Q4 2024 Tactical Idea List

Aug 13, 2024 09:28AM TD Cowen Reiterates Buy Rating on Annexon Biosciences (ANNX)

Aug 13, 2024 06:20AM H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

Aug 12, 2024 08:40AM Annexon, Inc. (ANNX) Reports In-Line Q2 EPS

Aug 6, 2024 09:24AM TD Cowen Reiterates Buy Rating on Annexon Biosciences (ANNX)

Jun 26, 2024 09:18AM TD Cowen Reiterates Buy Rating on Annexon Biosciences (ANNX)

Jun 25, 2024 05:00PM Annexon (ANNX) Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome

Apr 5, 2024 07:00PM These stocks are Wells Fargo's 14 high-conviction ideas for Q2